ES2621780T3 - Procedimiento de fabricación de vacunas - Google Patents

Procedimiento de fabricación de vacunas Download PDF

Info

Publication number
ES2621780T3
ES2621780T3 ES10179820.5T ES10179820T ES2621780T3 ES 2621780 T3 ES2621780 T3 ES 2621780T3 ES 10179820 T ES10179820 T ES 10179820T ES 2621780 T3 ES2621780 T3 ES 2621780T3
Authority
ES
Spain
Prior art keywords
saccharide
amino
carbodiimide
minutes
vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10179820.5T
Other languages
English (en)
Spanish (es)
Inventor
Ralph Leon Biemans
Pierre Duvivier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36716943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2621780(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0513071.1A external-priority patent/GB0513071D0/en
Priority claimed from GBGB0513069.5A external-priority patent/GB0513069D0/en
Priority claimed from GB0515556A external-priority patent/GB0515556D0/en
Priority claimed from GB0524204A external-priority patent/GB0524204D0/en
Priority claimed from GB0526040A external-priority patent/GB0526040D0/en
Priority claimed from GB0526041A external-priority patent/GB0526041D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of ES2621780T3 publication Critical patent/ES2621780T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Surgical Instruments (AREA)
ES10179820.5T 2005-06-27 2006-06-23 Procedimiento de fabricación de vacunas Active ES2621780T3 (es)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GBGB0513071.1A GB0513071D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GBGB0513069.5A GB0513069D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GB0513069 2005-06-27
GB0513071 2005-06-27
GB0515556 2005-07-28
GB0515556A GB0515556D0 (en) 2005-07-28 2005-07-28 Immunogenic composition
GB0524204 2005-11-28
GB0524204A GB0524204D0 (en) 2005-11-28 2005-11-28 Immunogenic composition
GB0526040 2005-12-21
GB0526040A GB0526040D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
GB0526041 2005-12-21
GB0526041A GB0526041D0 (en) 2005-12-21 2005-12-21 Immunogenic composition

Publications (1)

Publication Number Publication Date
ES2621780T3 true ES2621780T3 (es) 2017-07-05

Family

ID=36716943

Family Applications (9)

Application Number Title Priority Date Filing Date
ES10179820.5T Active ES2621780T3 (es) 2005-06-27 2006-06-23 Procedimiento de fabricación de vacunas
ES10158046.2T Active ES2662651T3 (es) 2005-06-27 2006-06-23 Composición inmunógena
ES15189397T Active ES2898451T3 (es) 2005-06-27 2006-06-23 Composición inmunogénica
ES06754596T Active ES2340711T3 (es) 2005-06-27 2006-06-23 Composicion inmunogena.
ES10177832T Active ES2750243T3 (es) 2005-06-27 2006-06-23 Composición de vacuna que comprende polisacáridos capsulares naturales conjugados de N. Meningitidis
ES06754599.6T Active ES2377075T5 (es) 2005-06-27 2006-06-23 Composición inmunogénica
ES06762248T Active ES2901378T3 (es) 2005-06-27 2006-06-23 Composición inmunogénica
ES06754582T Active ES2741529T3 (es) 2005-06-27 2006-06-23 Composición inmunogénica
ES14198052T Active ES2747025T3 (es) 2005-06-27 2006-06-23 Composición inmunógena

Family Applications After (8)

Application Number Title Priority Date Filing Date
ES10158046.2T Active ES2662651T3 (es) 2005-06-27 2006-06-23 Composición inmunógena
ES15189397T Active ES2898451T3 (es) 2005-06-27 2006-06-23 Composición inmunogénica
ES06754596T Active ES2340711T3 (es) 2005-06-27 2006-06-23 Composicion inmunogena.
ES10177832T Active ES2750243T3 (es) 2005-06-27 2006-06-23 Composición de vacuna que comprende polisacáridos capsulares naturales conjugados de N. Meningitidis
ES06754599.6T Active ES2377075T5 (es) 2005-06-27 2006-06-23 Composición inmunogénica
ES06762248T Active ES2901378T3 (es) 2005-06-27 2006-06-23 Composición inmunogénica
ES06754582T Active ES2741529T3 (es) 2005-06-27 2006-06-23 Composición inmunogénica
ES14198052T Active ES2747025T3 (es) 2005-06-27 2006-06-23 Composición inmunógena

Country Status (36)

Country Link
US (13) US8431136B2 (Direct)
EP (11) EP2201961B1 (Direct)
JP (9) JP5037503B2 (Direct)
KR (7) KR20130122810A (Direct)
CN (3) CN103083657B (Direct)
AP (1) AP2436A (Direct)
AR (3) AR056397A1 (Direct)
AT (3) ATE516816T1 (Direct)
AU (7) AU2006263965B2 (Direct)
BE (1) BE2012C042I2 (Direct)
BR (5) BRPI0612655B1 (Direct)
CA (5) CA2612963C (Direct)
CY (5) CY1109996T1 (Direct)
DE (1) DE602006013313D1 (Direct)
DK (7) DK1896061T3 (Direct)
EA (4) EA012506B1 (Direct)
ES (9) ES2621780T3 (Direct)
FR (1) FR22C1008I2 (Direct)
HR (4) HRP20110567T4 (Direct)
HU (7) HUE031380T2 (Direct)
IL (8) IL187924A (Direct)
LT (2) LT2351578T (Direct)
LU (2) LU92085I2 (Direct)
MA (4) MA29602B1 (Direct)
MX (5) MX2007016402A (Direct)
MY (3) MY148110A (Direct)
NL (2) NL300549I2 (Direct)
NO (4) NO345422B1 (Direct)
NZ (6) NZ564371A (Direct)
PE (6) PE20070123A1 (Direct)
PL (8) PL2283857T3 (Direct)
PT (8) PT1896065E (Direct)
SI (8) SI1896063T1 (Direct)
TW (5) TWI407970B (Direct)
UA (2) UA95238C2 (Direct)
WO (6) WO2007000322A1 (Direct)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070091698A (ko) * 2000-06-29 2007-09-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 다가 백신 조성물
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1587537B1 (en) 2003-01-30 2012-04-11 Novartis AG Injectable vaccines against multiple meningococcal serogroups
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
ES2621780T3 (es) 2005-06-27 2017-07-05 Glaxosmithkline Biologicals S.A. Procedimiento de fabricación de vacunas
AU2012261764B2 (en) * 2005-09-01 2016-09-08 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup C meningococcus
NZ598367A (en) * 2005-09-01 2013-10-25 Novartis Vaccines & Diagnostic Multiple vaccination including serogroup C meningococcus
KR101441368B1 (ko) 2005-12-22 2014-09-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 폐렴구균 다당류 컨쥬게이트 백신
NZ572054A (en) 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
DK2066344T3 (da) 2006-09-07 2011-09-05 Glaxosmithkline Biolog Sa Inaktiveret Poliovirus kombinationsvaccine
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
JP5476295B2 (ja) 2007-06-26 2014-04-23 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
PT2200642E (pt) 2007-10-19 2012-05-30 Novartis Ag Formulações de vacinas meningocócicas
MX2011002267A (es) * 2008-08-28 2011-03-30 Glaxosmithkline Biolog Sa Vacuna.
US11065323B2 (en) 2008-10-27 2021-07-20 Glaxosmithkline Biologicals Sa Purification method
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
EP2411048B1 (en) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
JP5668049B2 (ja) 2009-03-24 2015-02-12 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
JP5593626B2 (ja) * 2009-03-31 2014-09-24 凸版印刷株式会社 計量スプーン
PL2510947T3 (pl) 2009-04-14 2016-09-30 Kompozycje do immunizacji przeciwko Staphylococcus aureus
WO2010125480A1 (en) * 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
CN107096020A (zh) 2009-06-22 2017-08-29 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
MX2012000045A (es) * 2009-06-22 2012-01-30 Wyeth Llc Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de serotipo 5 y 8 de staphylococcus aureus.
CA2772916C (en) 2009-09-02 2019-01-15 Novartis Ag Immunogenic compositions including tlr activity modulators
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
PT2493498T (pt) 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
CN103189071A (zh) 2010-08-23 2013-07-03 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
SG187912A1 (en) 2010-09-10 2013-04-30 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CA2828844C (en) 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
JP2013112653A (ja) * 2011-11-30 2013-06-10 Jnc Corp 新規重合体およびその製造方法
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
CA2862247A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
HUE040914T4 (hu) * 2012-01-30 2019-05-28 Serum Institute Of India Pvt Ltd Immunogén készítmény
CA2861946A1 (en) 2012-02-02 2013-08-08 Novartis Ag Promoters for increased protein expression in meningococcus
CN102569723A (zh) * 2012-02-13 2012-07-11 华为技术有限公司 锂离子电池正极材料及其制备方法、正极及锂离子电池
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR101784142B1 (ko) 2012-03-09 2017-10-10 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP2892553A1 (en) 2012-09-06 2015-07-15 Novartis AG Combination vaccines with serogroup b meningococcus and d/t/p
ITMI20121597A1 (it) 2012-09-25 2014-03-26 Beta Pharma S A Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico
ES2672996T3 (es) 2012-10-02 2018-06-19 Glaxosmithkline Biologicals Sa Conjugados de sacáridos no lineales
DK2925355T3 (en) 2012-11-30 2018-01-15 Glaxosmithkline Biologicals Sa PSEUDOMONAS ANTIGENES AND ANTIGEN COMBINATIONS
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CA2894260A1 (en) 2012-12-18 2014-06-26 Glaxosmithkline Biologicals S.A. Conjugates for protecting against diphtheria and/or tetanus
CN105188747A (zh) 2013-02-01 2015-12-23 葛兰素史密斯克莱生物公司 包含toll样受体激动剂的免疫组合物的皮内递送
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
PT2976101T (pt) * 2013-03-18 2020-11-12 Glaxosmithkline Biologicals Sa Método de tratamento
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
IN2014DE02450A (Direct) 2013-09-25 2015-06-26 Suzuki Motor Corp
RU2535122C1 (ru) * 2013-11-06 2014-12-10 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения холерогена-анатоксина
EP3607966A1 (en) * 2014-01-21 2020-02-12 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
EP3131576B1 (en) 2014-04-17 2021-06-30 Medizinische Hochschule Hannover Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity
EP3270959A1 (en) 2015-02-19 2018-01-24 Pfizer Inc Neisseria meningitidis compositions and methods thereof
EP4649956A2 (en) * 2015-07-21 2025-11-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20170333546A1 (en) * 2015-12-08 2017-11-23 Jl Medical Corporation Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein
MY199399A (en) * 2016-03-15 2023-10-25 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Novel polysaccharide-protein conjugates and process to obtain thereof
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
CN109890413B (zh) * 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
EP3639848A3 (en) 2016-09-13 2020-12-16 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
CN109922828A (zh) * 2016-10-20 2019-06-21 Km生物医药股份公司 使用具有降低了的分子量的PRP的Hib结合疫苗的制造方法
KR20190103256A (ko) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
JP7218358B2 (ja) 2017-09-07 2023-02-06 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用
WO2019145981A1 (en) * 2018-01-29 2019-08-01 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
AU2020355401B2 (en) 2019-09-27 2025-03-27 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021099982A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
MX2023005517A (es) 2020-11-13 2023-08-21 Glaxosmithkline Biologicals Sa Novedosos portadores y métodos de conjugación.
RU2770877C1 (ru) * 2021-04-08 2022-04-22 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ получения антигенной конъюгированной субстанции гемофильного типа b микроба для создания вакцинных препаратов
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
WO2025021710A1 (en) 2023-07-21 2025-01-30 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB513069A (en) 1937-04-24 1939-10-03 Linde Air Prod Co Improvements in method of and apparatus for the treatment of metallic bodies by oxidising gas
GB505518A (en) 1938-02-03 1939-05-12 Daniel Morgan Skeins Improvements in or relating to envelopes
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4123520A (en) * 1977-08-01 1978-10-31 Merck & Co., Inc. Method for preparing high molecular weight meningococcal Group C vaccine
DE2748132A1 (de) * 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4235994A (en) * 1978-06-26 1980-11-25 Merck & Co., Inc. High molecular weight meningococcal group C vaccine and method for preparation thereof
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
DE3040825A1 (de) * 1980-10-30 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach Neues tridekapeptid, verfahren zu seiner herstellung und verwendung
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
HU193083B (en) * 1984-02-22 1987-08-28 Sandoz Ag Process for preparing diazepinoindole derivatives further pharmaceutical compositions containing such compounds
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3526940A1 (de) 1985-07-27 1987-02-12 Siegfried Fricker Anker zum einbetonieren in schwere lasten
IL78929A0 (en) * 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
RU2023448C1 (ru) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
US5180815A (en) * 1988-04-13 1993-01-19 Fuji Photo Film Co., Ltd. Modified protein for carrying hapten
EP0417177B1 (de) 1988-05-31 1993-10-27 Beatrice KÖNIG-HAUG Regalsystem
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
KR920703114A (ko) 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
RU2105568C1 (ru) 1989-12-14 1998-02-27 Нэшнл Рисерч Каунсл Оф Канада Полисахарид neisseria meningitidis с модифицированной группой b, конъюгированный антиген, вакцина против менингита группы b и способ индукции ответа антител к менингиту группы b
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
GB2264352A (en) 1992-01-31 1993-08-25 Richards Eng Ltd Incineration apparatus
DE69333107T2 (de) 1992-02-11 2004-01-29 Jackson H M Found Military Med Dualer träger für immunogene konstrukte
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
AU4230493A (en) * 1992-05-06 1993-11-29 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
DK0835663T3 (da) 1992-05-23 2010-02-01 Glaxosmithkline Biolog Sa Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
SG47725A1 (en) 1992-10-27 1998-04-17 American Cyanamid Co Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
WO1994014086A1 (en) 1992-12-14 1994-06-23 Western Atlas International, Inc. Removable piston bore liner for hydraulically actuated seismic vibrator
WO1995008348A1 (en) 1993-09-22 1995-03-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
US5849301A (en) 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
US5869058A (en) 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
JPH11502820A (ja) 1995-03-22 1999-03-09 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 有機シアン化試薬により活性化された可溶性炭水化物を使用する免疫原性構築物の製造
JP4233113B2 (ja) 1995-06-07 2009-03-04 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン
KR100425929B1 (ko) 1995-06-23 2004-05-31 글락소스미스클라인 바이오로지칼즈 에스.에이. 알루미늄포스페이트상에흡착된다당류컨쥬게이트항원을포함하는백신조성물
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
ID21646A (id) 1996-10-23 1999-07-08 Matsushita Electric Industrial Co Ltd Piringan optik
JP2001501833A (ja) 1996-10-31 2001-02-13 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅのポリヌクレオチドおよび配列
WO1998026799A1 (en) 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugate vaccine for salmonella paratyphi a
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
DE69735191T2 (de) 1997-09-15 2006-10-05 Sanofi Pasteur Msd Verfahren zur Herstellung multivalenter Impfstoffe
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
JP2002513028A (ja) * 1998-04-28 2002-05-08 ガレニカ ファーマシューティカルズ， インコーポレイテッド ポリサッカリド抗原結合体
HUP0103100A3 (en) 1998-08-19 2005-11-28 Baxter Healthcare Sa Immunogenic betha-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
WO2000033882A1 (en) † 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
PT1140157E (pt) 1998-12-21 2009-05-06 Medimmune Inc Proteínas de streptococcus pneumoniae e fragmentos imunogénicos para vacinas
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
ATE297190T1 (de) 1999-02-26 2005-06-15 Chiron Corp Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
AR022964A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Biolog Vacuna
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
JP4660043B2 (ja) * 1999-06-25 2011-03-30 ワイス・ホールディングズ・コーポレイション グラム陰性細菌のペプチドグリカン結合リポタンパク質の脂質化された形態の製造
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
EP1233784B1 (en) 1999-12-02 2008-07-09 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for stabilizing biological molecules upon lyophilization
FR2806304B1 (fr) 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
KR20070091698A (ko) * 2000-06-29 2007-09-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 다가 백신 조성물
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2416137C (en) * 2000-07-27 2013-01-29 Dan Granoff Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
DE60139563D1 (de) * 2000-10-27 2009-09-24 Craig J Venter Inst Inc Nukleinsäuren und proteine von gruppen a und b-streptokokken
ES2544979T3 (es) * 2001-01-23 2015-09-07 Sanofi Pasteur Inc. Vacuna de conjugado de polisacárido-CRM197 meningocócica tri- o tetravalente
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
US6615062B2 (en) 2001-05-31 2003-09-02 Infraredx, Inc. Referencing optical catheters
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
IL163988A0 (en) 2002-03-15 2005-12-18 Wyeth Corp Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
BR0308768A (pt) 2002-03-26 2005-02-15 Chiron Srl Sacarìdeos modificados possuindo estabilidade melhorada em água
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
DE60328481D1 (de) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
CN1684707B (zh) 2002-05-14 2012-09-05 诺华疫苗和诊断有限公司 用于细菌性脑膜炎的粘膜结合疫苗
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
US20060034854A1 (en) 2002-08-02 2006-02-16 Berthet Francois-Xavier J Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0220199D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ES2608048T3 (es) * 2002-10-11 2017-04-05 Glaxosmithkline Biologicals Sa Vacunas polipeptídicas para protección amplia contra linajes meningocócicos hipervirulentos
CN1401328A (zh) 2002-10-18 2003-03-12 北京绿竹生物技术有限责任公司 流行性脑脊髓膜炎多糖－蛋白结合疫苗
MXPA05004528A (es) * 2002-11-01 2005-07-26 Glaxosmithkline Biolog Sa Composicion inmunogenica.
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CN1168501C (zh) 2002-12-27 2004-09-29 北京绿竹生物技术有限责任公司 一种多糖-蛋白结合疫苗
EP1587537B1 (en) 2003-01-30 2012-04-11 Novartis AG Injectable vaccines against multiple meningococcal serogroups
WO2004081515A2 (en) * 2003-03-13 2004-09-23 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
CA2519511A1 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
JP2006528936A (ja) * 2003-05-07 2006-12-28 アヴェンティス パストゥール インコーポレイテッド 多価髄膜炎菌誘導体化多糖−タンパク質複合体およびワクチン
WO2005020964A1 (en) 2003-06-02 2005-03-10 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
EP2364725A3 (en) * 2003-06-23 2012-05-09 Sanofi Pasteur Inc. Immunization method against neisseria meningitidis serogroups a and c
KR101034055B1 (ko) 2003-07-18 2011-05-12 엘지이노텍 주식회사 발광 다이오드 및 그 제조방법
AU2004281630A1 (en) * 2003-08-06 2005-04-28 Bio-Manguinhos/Fiocruz Process for preparing polysaccharide-protein conjugate vaccines
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US6995363B2 (en) * 2003-08-21 2006-02-07 Applera Corporation Reduction of matrix interference for MALDI mass spectrometry analysis
BRPI0415025A (pt) 2003-10-02 2006-12-12 Chiron Srl vacinas lìquidas para sorogrupos meningocócicos múltiplos
WO2005032584A2 (en) 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
JP5173194B2 (ja) 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
ES2409782T3 (es) 2004-04-05 2013-06-27 Zoetis P Llc Emulsiones de aceite en agua microfluidificadas y composiciones de vacuna
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
DK1740217T3 (da) 2004-04-30 2011-09-26 Novartis Ag Meningokok-konjugat-vaccination
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
NZ553775A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition for use in vaccination against staphylococcei
US20060121055A1 (en) 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
JP2008529558A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 髄膜炎／敗血症に関連する大腸菌由来のタンパク質および核酸
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
KR101298053B1 (ko) 2005-04-08 2013-08-20 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CN101282984B (zh) * 2005-05-06 2013-05-08 诺华疫苗与诊断股份有限公司 A型脑膜炎疫苗的免疫原
ES2621780T3 (es) * 2005-06-27 2017-07-05 Glaxosmithkline Biologicals S.A. Procedimiento de fabricación de vacunas
CN1709505B (zh) 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
NZ598367A (en) * 2005-09-01 2013-10-25 Novartis Vaccines & Diagnostic Multiple vaccination including serogroup C meningococcus
US8679770B2 (en) * 2005-09-05 2014-03-25 Glaxo Smith Kline Biologicals S.A. Serum bactericidal assay for N. meningitidis specific antisera
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
KR101441368B1 (ko) * 2005-12-22 2014-09-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 폐렴구균 다당류 컨쥬게이트 백신
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EA200801368A1 (ru) 2005-12-23 2008-12-30 Глаксосмитклайн Байолоджикалс С.А. Конъюгатные вакцины
KR101838938B1 (ko) * 2006-03-17 2018-03-15 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
EP1998802A2 (en) * 2006-03-30 2008-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
NZ573931A (en) * 2006-06-29 2012-03-30 Craig J Venter Inst Inc Polypeptides from neisseria meningitidis
US7491517B2 (en) * 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
KR20090060410A (ko) 2006-07-21 2009-06-12 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 인간 내인성 레트로바이러스 폴리펩타이드 조성물 및 이들의 사용 방법
DK2066344T3 (da) 2006-09-07 2011-09-05 Glaxosmithkline Biolog Sa Inaktiveret Poliovirus kombinationsvaccine
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
JP4858611B2 (ja) 2007-03-14 2012-01-18 コニカミノルタビジネステクノロジーズ株式会社 情報埋め込み方法、そのプログラムおよび情報埋め込み装置
EP2682127A1 (en) 2007-05-02 2014-01-08 GlaxoSmithKline Biologicals S.A. Vaccine
JP5637848B2 (ja) 2007-06-04 2014-12-10 ノバルティス アーゲー 髄膜炎ワクチンの製剤化
JP5476295B2 (ja) 2007-06-26 2014-04-23 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
MX2011002267A (es) * 2008-08-28 2011-03-30 Glaxosmithkline Biolog Sa Vacuna.
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
US8259461B2 (en) * 2008-11-25 2012-09-04 Micron Technology, Inc. Apparatus for bypassing faulty connections
MX373250B (es) * 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2545068B8 (en) * 2010-03-11 2018-03-21 GlaxoSmithKline Biologicals S.A. Immunogenic composition or vaccine against gram-negative bacterial, for example neiserial, infection or disease
WO2011155196A1 (ja) * 2010-06-11 2011-12-15 パナソニック株式会社 語音聴取の評価システム、その方法およびそのプログラム
MX354924B (es) * 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
HUE040914T4 (hu) * 2012-01-30 2019-05-28 Serum Institute Of India Pvt Ltd Immunogén készítmény
EP2852414B9 (en) * 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningococcus serogroup x conjugate
WO2014001328A1 (en) 2012-06-25 2014-01-03 Nadiro A/S A lifeboat deployment unit
PT3513806T (pt) * 2012-12-05 2023-03-02 Glaxosmithkline Biologicals Sa Composição imunogénica
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
CN108064174A (zh) * 2014-08-05 2018-05-22 葛兰素史密丝克莱恩生物有限公司 抗原的载体分子
TWI715617B (zh) * 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CN109890413B (zh) * 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
US11951165B2 (en) * 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
SG10202111092UA (en) * 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
BR112020000999A2 (pt) * 2017-07-18 2020-07-14 Serum Institute Of India Pvt Ltd. composição imunogênica tendo estabilidade aperfeiçoada, imunogenicidade melhorada e reatogenicidade reduzida e processo para a sua preparação

Also Published As

Publication number Publication date
JP2008543908A (ja) 2008-12-04
AR056396A1 (es) 2007-10-10
HK1114011A1 (en) 2008-10-24
AR056397A1 (es) 2007-10-10
PL1896061T3 (pl) 2020-02-28
US9931397B2 (en) 2018-04-03
EP2283857A1 (en) 2011-02-16
TWI537001B (zh) 2016-06-11
TW201414490A (zh) 2014-04-16
PE20070499A1 (es) 2007-05-21
TW201336507A (zh) 2013-09-16
NO342815B1 (no) 2018-08-13
CA2612980A1 (en) 2007-01-04
US20150044253A1 (en) 2015-02-12
WO2007000342A3 (en) 2007-05-31
SI2283857T1 (sl) 2019-11-29
HUS1200023I1 (hu) 2021-03-29
NZ564606A (en) 2010-10-29
DK1896062T3 (da) 2010-06-28
CY1109996T1 (el) 2014-09-10
EA200702577A1 (ru) 2008-06-30
TW200730187A (en) 2007-08-16
JP2013018798A (ja) 2013-01-31
HRP20110567T4 (xx) 2015-01-16
CA2612963C (en) 2016-10-18
PT3009146T (pt) 2021-11-30
IL213718A (en) 2013-07-31
KR20080024222A (ko) 2008-03-17
KR101408113B1 (ko) 2014-06-16
EP2201961A1 (en) 2010-06-30
SI1896065T1 (sl) 2011-10-28
MA29603B1 (fr) 2008-07-01
PT1896062E (pt) 2010-05-17
IL188045A0 (en) 2008-03-20
KR101351873B1 (ko) 2014-02-17
AU2010203115A1 (en) 2010-08-12
EP1896064A2 (en) 2008-03-12
NO20076343L (no) 2008-03-25
EP1896065B1 (en) 2011-07-20
LTC1896065I2 (lt) 2025-06-10
US20090252759A1 (en) 2009-10-08
ES2377075T3 (es) 2012-03-22
CN102526723A (zh) 2012-07-04
ES2747025T3 (es) 2020-03-09
JP2015134829A (ja) 2015-07-27
AU2006263965A1 (en) 2007-01-04
AU2006263944A1 (en) 2007-01-04
NO345305B1 (no) 2020-12-07
IL188072A (en) 2017-07-31
EP1896065B2 (en) 2014-09-03
WO2007000314A3 (en) 2007-05-31
IL213718A0 (en) 2011-07-31
PT1896061T (pt) 2019-08-01
SI2351578T1 (sl) 2017-05-31
UA95238C2 (uk) 2011-07-25
ES2377075T5 (es) 2016-04-29
NL301151I2 (nl) 2025-12-15
US9486515B2 (en) 2016-11-08
DK2878307T3 (da) 2019-10-07
AP2436A (en) 2012-08-31
EP1896066A2 (en) 2008-03-12
WO2007000322A1 (en) 2007-01-04
US20080199490A1 (en) 2008-08-21
WO2007000343A2 (en) 2007-01-04
PE20110096A1 (es) 2011-03-07
JP5718960B2 (ja) 2015-05-13
US20090136541A1 (en) 2009-05-28
DE602006013313D1 (de) 2010-05-12
EP1896062B1 (en) 2010-03-31
NZ564607A (en) 2011-06-30
NL300549I2 (Direct) 2017-01-03
US8398983B2 (en) 2013-03-19
BRPI0612656B1 (pt) 2021-09-08
BRPI0612655A8 (pt) 2018-01-30
EA012506B1 (ru) 2009-10-30
CA2611964C (en) 2016-11-08
CA2612980C (en) 2019-01-15
KR20080018226A (ko) 2008-02-27
EP1896061B1 (en) 2019-06-12
JP2008543904A (ja) 2008-12-04
EA012214B1 (ru) 2009-08-28
AU2006263963A1 (en) 2007-01-04
MX2007016236A (es) 2008-03-07
EP1896063A1 (en) 2008-03-12
BRPI0612656A8 (pt) 2018-01-23
LU92085I2 (fr) 2012-12-19
SI2878307T1 (sl) 2019-11-29
CN103083657A (zh) 2013-05-08
HUE046905T2 (hu) 2020-03-30
LU92085I9 (Direct) 2019-01-04
PT2283857T (pt) 2019-10-24
AU2006263964A1 (en) 2007-01-04
ES2741529T3 (es) 2020-02-11
JP5965512B2 (ja) 2016-08-03
DK2283857T3 (da) 2019-10-28
EP2283857B1 (en) 2019-07-24
CA2612963A1 (en) 2007-01-04
US10166287B2 (en) 2019-01-01
NO20076363L (no) 2008-03-26
JP5037503B2 (ja) 2012-09-26
DK1896065T4 (da) 2014-10-20
SI1896065T2 (sl) 2014-12-31
AU2006263964B2 (en) 2010-05-20
PL3009146T3 (pl) 2022-02-07
MY147490A (en) 2012-12-14
BRPI0612654B8 (pt) 2021-05-25
MX2007016405A (es) 2008-03-07
EA200702576A1 (ru) 2008-06-30
CA2611964A1 (en) 2007-01-04
MA29569B1 (fr) 2008-06-02
EP1896063B1 (en) 2011-12-14
FR22C1008I1 (fr) 2022-04-29
HUE045482T2 (hu) 2019-12-30
EP2351578B1 (en) 2017-01-18
HUE056842T2 (hu) 2022-03-28
US9358279B2 (en) 2016-06-07
LTPA2012019I1 (lt) 2012-11-26
UA95237C2 (uk) 2011-07-25
PL1896063T3 (pl) 2012-04-30
CA2612957C (en) 2016-07-19
EP1896066B1 (en) 2021-10-27
US20180064806A1 (en) 2018-03-08
CY1118646T1 (el) 2017-07-12
PT1896065E (pt) 2011-08-31
CA2611960A1 (en) 2007-01-04
KR101532068B1 (ko) 2015-06-29
MX2007016403A (es) 2008-03-07
HK1116414A1 (en) 2008-12-24
EP3009146A1 (en) 2016-04-20
BRPI0612654B1 (pt) 2021-05-04
PE20070123A1 (es) 2007-02-08
AU2010203115B2 (en) 2012-03-15
EA012528B1 (ru) 2009-10-30
CY1111827T1 (el) 2015-10-07
PE20110072A1 (es) 2011-02-04
BRPI0612655A2 (pt) 2010-11-30
IL188046A (en) 2012-03-29
US20130171188A1 (en) 2013-07-04
TWI407970B (zh) 2013-09-11
EP2201961B1 (en) 2018-01-24
HK1116413A1 (en) 2008-12-24
PT1896063E (pt) 2012-02-13
CN102218138A (zh) 2011-10-19
AU2010212417A1 (en) 2010-09-09
US8431136B2 (en) 2013-04-30
US20080193476A1 (en) 2008-08-14
HUE031380T2 (en) 2017-07-28
CA2612957A1 (en) 2007-01-04
NZ564370A (en) 2011-10-28
ATE516816T1 (de) 2011-08-15
AR053935A1 (es) 2007-05-23
AP2007004274A0 (en) 2007-12-31
KR101351870B1 (ko) 2014-02-17
BRPI0612669B8 (pt) 2021-05-25
JP5731737B2 (ja) 2015-06-10
AU2006263965B2 (en) 2012-09-13
BRPI0612655B1 (pt) 2021-06-15
BRPI0612669A2 (pt) 2010-11-30
BRPI0612670B8 (pt) 2021-05-25
SI1896062T1 (sl) 2010-07-30
WO2007000342A2 (en) 2007-01-04
US20200000911A1 (en) 2020-01-02
IL213795A (en) 2013-05-30
BRPI0612670A2 (pt) 2010-11-30
NO345422B1 (no) 2021-01-25
KR101359953B1 (ko) 2014-02-21
MY147783A (en) 2013-01-31
KR101321056B1 (ko) 2013-10-30
CY1112698T1 (el) 2016-02-10
JP2008543907A (ja) 2008-12-04
KR20080018216A (ko) 2008-02-27
PT2351578T (pt) 2017-04-07
PE20142165A1 (es) 2015-01-09
US20170065714A1 (en) 2017-03-09
EP2878307B1 (en) 2019-07-24
LUC00247I2 (Direct) 2024-10-04
EA200702575A1 (ru) 2008-06-30
EP1896061A2 (en) 2008-03-12
AU2006263936A1 (en) 2007-01-04
ATE536884T1 (de) 2011-12-15
HRP20100211T1 (hr) 2010-05-31
JP2008543905A (ja) 2008-12-04
EP1896066B8 (en) 2022-01-19
NZ564605A (en) 2011-01-28
ES2340711T3 (es) 2010-06-08
IL187924A0 (en) 2008-03-20
NO20076302L (no) 2008-03-26
PL2878307T3 (pl) 2020-01-31
CN102526723B (zh) 2017-07-07
WO2007000341A2 (en) 2007-01-04
HUS2200002I1 (hu) 2022-12-28
NZ590204A (en) 2012-02-24
WO2007000314A2 (en) 2007-01-04
DK1896061T3 (da) 2019-08-26
JP5769688B2 (ja) 2015-08-26
EP1896063B2 (en) 2016-03-02
JP2013107913A (ja) 2013-06-06
SI1896061T1 (sl) 2019-10-30
HRP20110567T1 (en) 2011-09-30
JP2008543909A (ja) 2008-12-04
EP2351578A1 (en) 2011-08-03
PT2878307T (pt) 2019-10-24
MX2007016237A (es) 2008-03-07
US10245317B2 (en) 2019-04-02
CA2611960C (en) 2015-05-05
SI3009146T1 (sl) 2022-02-28
CY2012027I2 (el) 2015-10-07
ES2898451T3 (es) 2022-03-07
CN103083657B (zh) 2016-06-08
NO20076350L (no) 2008-03-26
PL1896065T3 (pl) 2011-12-30
BRPI0612654A2 (pt) 2012-10-02
PL2283857T3 (pl) 2020-02-28
US11241495B2 (en) 2022-02-08
EP2878307A1 (en) 2015-06-03
NO344452B1 (no) 2019-12-09
PL1896065T5 (pl) 2014-12-31
EP1896065A2 (en) 2008-03-12
DK1896065T3 (da) 2011-08-29
US9789179B2 (en) 2017-10-17
HUE047211T2 (hu) 2020-04-28
EA013374B1 (ru) 2010-04-30
CY2012027I1 (el) 2015-10-07
NZ564371A (en) 2010-05-28
HK1206587A1 (en) 2016-01-15
AU2006263963B2 (en) 2010-05-13
PL2351578T3 (pl) 2017-07-31
US8329184B2 (en) 2012-12-11
MX2007016402A (es) 2008-03-07
WO2007000327A1 (en) 2007-01-04
TW200738259A (en) 2007-10-16
TWI422386B (zh) 2014-01-11
WO2007000343A3 (en) 2007-05-31
MY148110A (en) 2013-02-28
BRPI0612656A2 (pt) 2010-11-30
US8846049B2 (en) 2014-09-30
SI1896063T1 (sl) 2012-03-30
US20100215686A1 (en) 2010-08-26
EA200702574A1 (ru) 2008-06-30
US20090041802A1 (en) 2009-02-12
ATE462444T1 (de) 2010-04-15
AU2010203115C1 (en) 2013-05-02
DK1896063T3 (da) 2012-03-19
HRP20170457T1 (hr) 2017-05-19
EP1896062A1 (en) 2008-03-12
PL1896062T3 (pl) 2010-08-31
EP3009146B1 (en) 2021-10-20
IL188072A0 (en) 2008-03-20
DK2351578T3 (en) 2017-04-24
WO2007000341A3 (en) 2007-05-31
IL214657A0 (en) 2011-09-27
US8883163B2 (en) 2014-11-11
FR22C1008I2 (fr) 2024-01-19
AU2006263936B2 (en) 2010-05-20
US20130004532A1 (en) 2013-01-03
AU2006263944B2 (en) 2012-03-01
IL187924A (en) 2011-11-30
IL213795A0 (en) 2011-07-31
ES2750243T3 (es) 2020-03-25
PE20070163A1 (es) 2007-03-01
KR20080030577A (ko) 2008-04-04
MA29602B1 (fr) 2008-07-01
HRP20120102T1 (hr) 2012-02-29
US20190298822A1 (en) 2019-10-03
JP2013209395A (ja) 2013-10-10
IL222346A (en) 2015-07-30
JP5297800B2 (ja) 2013-09-25
MA29993B1 (fr) 2008-12-01
KR20080025184A (ko) 2008-03-19
ES2662651T3 (es) 2018-04-09
HUS000497I2 (hu) 2021-03-29
TWI477283B (zh) 2015-03-21
WO2007000342A8 (en) 2008-07-10
BRPI0612669B1 (pt) 2019-08-13
BRPI0612670B1 (pt) 2020-04-28
KR20130086087A (ko) 2013-07-30
BE2012C042I2 (Direct) 2021-07-19
IL188046A0 (en) 2008-03-20
ES2901378T3 (es) 2022-03-22
JP5280199B2 (ja) 2013-09-04
KR20130122810A (ko) 2013-11-08
LT2351578T (lt) 2017-04-10

Similar Documents

Publication Publication Date Title
ES2621780T3 (es) Procedimiento de fabricación de vacunas
ES2820824T3 (es) Composiciones inmunogénicas que comprenden antígenos sacáridos capsulares conjugados y usos de las mismas
KR20250058066A (ko) 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
ES2367918T5 (es) Procedimiento de fabricación de vacunas
CN116744965A (zh) 用于肺炎球菌疫苗的免疫原性组合物
RU2827429C1 (ru) Иммуногенные композиции для применения в пневмококковых вакцинах
HK40090692A (zh) 用於肺炎球菌疫苗的免疫原性组合物
HK1153679A (en) Process for manufacturing vaccines
HK1114011C (en) Process for manufacturing vaccines
HK1114011B (en) Process for manufacturing vaccines